Navigation Links
SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
Date:4/28/2009

HOUSTON, April 28 /PRNewswire/ -- SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced today its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma. SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.

Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair. However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.

"The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians," said PharmaGenoma, CEO Andy Goren.

About SeqWright

Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services, inclucing next generation sequencing. For over fifteen years, SeqWright has provided state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials. SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with its CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the United States. For additional information about SeqWright and its services, please visit www.seqwright.com.

About PharmaGenoma, Inc.

PharmaGenoma, Inc. Based in Irvine, CA, USA is a molecular dermatology research and development company. PharmaGenoma and its subsidary HairDX market the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual's genetic make up. PharmaGenoma uses only CLIA certified laboratories (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. The HairDX test collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device.


'/>"/>
SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SeqWright to Invest in LaserGens Novel Lightning Terminators(TM)
2. California Grants SeqWright License to Operate as a Clinical Laboratory
3. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
4. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
5. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
6. Microtest Labs Expands Clean Room, Contamination Testing Services
7. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
8. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
9. Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer
10. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
11. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome workshop with ... surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition of MRI ... state-of-the-art technology and only 1 of about 3 currently available in the United States. ...
(Date:5/27/2016)... ... ... Doctors in Italy, Japan, the UK and the US have reached some surprising ... its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details of their ... , The studies analyzed for the new report included more than 3,447 cancer patients. ...
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... New Jersey and READING, ... Indegene ( http://www.indegene.com ), a leading ... to life science, pharmaceutical and healthcare organisations and ... of innovative scientific support throughout the product lifecycle, ... with the launch of IntraScience.      ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/15/2016)... ALBANY, New York , March 15, 2016 ... a new market report published by Transparency Market Research "Digital ... Growth, Trends and Forecast 2015 - 2023," the global digital ... at US$ 731.9 Mn in 2014 and is forecast to ... to 2023. Growth of micro, small and medium enterprises (MSMEs) ...
Breaking Biology News(10 mins):